{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:46:42Z","timestamp":1785847602435,"version":"3.56.0"},"reference-count":40,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Research Advancement in Palliative Medicine, Japanese Society for Palliative Medicine","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Methadone exerts analgesic effects through \u03bc-opioid receptor affinity and N-methyl-D-aspartate receptor antagonism, which may benefit refractory cancer pain with neuropathic components. Methadone can be introduced by the \u2018stop-and-go\u2019 (SAG) method or the \u2018add-on\u2019 (AO) method, in which low-dose methadone is added to existing opioids. Observational studies suggest AO may improve pain control but no double-blind randomised controlled trial (RCT) has evaluated this approach. Therefore, the primary aim of this study is to assess the feasibility of conducting a double-blind RCT comparing methadone AO therapy with opioid dose escalation according to standard practice for refractory cancer pain while also exploring safety and preliminary efficacy signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A two-centre, randomised, double-blind, two-arm feasibility trial will enrol 22 patients with advanced or recurrent cancer and inadequately controlled pain (oral morphine equivalent daily dose 60\u2013300\u2009mg). Participants will be allocated 1:1 to the methadone AO or opioid-escalation group using a web-based randomisation system with the minimisation method. The primary endpoint is the completion rate of the 2-week study treatment. Secondary outcomes include pain intensity (Brief Pain Inventory), time to adequate pain control, achievement of a personalised pain goal, adverse events (Common Terminology Criteria for Adverse Events (CTCAE)\/Patient-Reported Outcomes version of the CTCAE) and quality of life (European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Core 15-PAL). Feasibility will be determined based on achieving a treatment completion rate of 70% or higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by the Certified Review Board of the National Cancer Centre Hospital (CRB3180008). Written informed consent will be obtained from all participants. The trial is registered in the Japan Registry of Clinical Trials. Results will be published in peer-reviewed journals and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCTs031240220.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-119999","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:56:41Z","timestamp":1785844601000},"page":"e119999","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23\/NCCH2309 \u2013 protocol"],"prefix":"10.1136","volume":"16","author":[{"given":"Takako","family":"Ikegami","sequence":"first","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"},{"name":"Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Oyamada","sequence":"additional","affiliation":[{"name":"Biostatistics, Japanese Organisation for Research and Treatment of Cancer, Arakawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ariyoshi","sequence":"additional","affiliation":[{"name":"Data Center, Japanese Organisation for Research and Treatment of Cancer, Arakawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naho","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-2293","authenticated-orcid":false,"given":"Naruaki","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-2161","authenticated-orcid":false,"given":"Hiroto","family":"Ishiki","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"},{"name":"Department of Palliative and Supportive Care Development, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center East Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Breast Oncology Service, Saitama Medical University International Medical Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-4818","authenticated-orcid":false,"given":"Yoshihisa","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan"},{"name":"Department of Palliative and Supportive Care Development, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7276-1971","authenticated-orcid":false,"given":"Hiromichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Palliative and Supportive Care Development, National Cancer Center Hospital, Tokyo, Japan"},{"name":"Department of Psycho-oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026080404552371000_16.8.e119999.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60236-5"},{"key":"2026080404552371000_16.8.e119999.2","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200609000-00002"},{"key":"2026080404552371000_16.8.e119999.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"2026080404552371000_16.8.e119999.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)13391-2"},{"key":"2026080404552371000_16.8.e119999.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01573-1"},{"key":"2026080404552371000_16.8.e119999.6","first-page":"435","article-title":"Pharmacology of methadone and its isomers","volume":"71","author":"Inturrisi","year":"2005","journal-title":"Minerva Anestesiol"},{"key":"2026080404552371000_16.8.e119999.7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/jpm.2019.0253","article-title":"The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care","volume":"23","author":"F\u00fcrst","year":"2020","journal-title":"J Palliat Med"},{"key":"2026080404552371000_16.8.e119999.8","article-title":"Low-dose methadone added to another opioid for cancer pain: a multicentre prospective study","volume":"32","author":"Treillet","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026080404552371000_16.8.e119999.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2008.01.013"},{"key":"2026080404552371000_16.8.e119999.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.172"},{"key":"2026080404552371000_16.8.e119999.11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/papr.12609","article-title":"Methadone versus Fentanyl in Patients with Radiation-Induced Nociceptive Pain with Head and Neck Cancer: A Randomized Controlled Noninferiority Trial","volume":"18","author":"Haumann","year":"2018","journal-title":"Pain Pract"},{"key":"2026080404552371000_16.8.e119999.12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2016.06.025","article-title":"Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer","volume":"65","author":"Haumann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026080404552371000_16.8.e119999.13","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1200\/JCO.1998.16.11.3656","article-title":"Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home","volume":"16","author":"Mercadante","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026080404552371000_16.8.e119999.14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0885-3924(86)80042-2","article-title":"A randomized study on oral administration of morphine and methadone in the treatment of cancer pain","volume":"1","author":"Ventafridda","year":"1986","journal-title":"J Pain Symptom Manage"},{"key":"2026080404552371000_16.8.e119999.15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196783415"},{"key":"2026080404552371000_16.8.e119999.16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.1977.tb00433.x","article-title":"A comparison of diamorphine-with-cocaine and methadone","volume":"4","author":"Twycross","year":"1977","journal-title":"Brit J Clinical Pharma"},{"key":"2026080404552371000_16.8.e119999.17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jpainsymman.2016.05.022","article-title":"Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain)","volume":"52","author":"Poulain","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2026080404552371000_16.8.e119999.18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/AJP.0000000000000959","article-title":"A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain","volume":"37","author":"Duarte","year":"2021","journal-title":"Clin J Pain"},{"key":"2026080404552371000_16.8.e119999.19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/jpm.2020.0244","article-title":"Switching Ratio from Parenteral to Oral Methadone 1:1.2 Is Safer Compared with Ratio 1:2 in Patients with Controlled Cancer Pain: A Multicenter Randomized-Controlled Trial (RATIOMTD-010810)","volume":"24","author":"Gonz\u00e1lez-Barboteo","year":"2021","journal-title":"J Palliat Med"},{"key":"2026080404552371000_16.8.e119999.20","article-title":"Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study","volume":"32","author":"Sulistio","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026080404552371000_16.8.e119999.21","unstructured":"Cleeland CS . Measurement of pain by subjective report. In: Chapman CRL , ed. Advances in pain research and therapy. volume 12: issues in pain measurement. New York: Raven Press, 1989: 391\u2013403."},{"key":"2026080404552371000_16.8.e119999.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.02.007"},{"key":"2026080404552371000_16.8.e119999.23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/pme.12468","article-title":"Validity, Reliability, and Assessment Sensitivity of the Japanese Version of the Short-Form McGill Pain Questionnaire 2 in Japanese Patients with Neuropathic and Non-Neuropathic Pain","volume":"15","author":"Maruo","year":"2014","journal-title":"Pain Med"},{"key":"2026080404552371000_16.8.e119999.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.022"},{"key":"2026080404552371000_16.8.e119999.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9939-y"},{"key":"2026080404552371000_16.8.e119999.26","unstructured":"National Cancer Institute; National Institutes of Health, U.S. Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.html"},{"key":"2026080404552371000_16.8.e119999.27","unstructured":"Japan Clinical Oncology Group (JCOG) . Common terminology criteria for adverse events (CTCAE) version 5.0: Japanese translation (JCOG version). 2018. Available: https:\/\/jcog.jp\/doctor\/tool\/ctcaev5.html"},{"key":"2026080404552371000_16.8.e119999.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0470-1"},{"key":"2026080404552371000_16.8.e119999.29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026080404552371000_16.8.e119999.30","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-017-0012-7","article-title":"Japanese translation and linguistic validation of the US National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Miyaji","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2026080404552371000_16.8.e119999.31","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-017-0022-5","article-title":"The Japanese version of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events","volume":"2","author":"Kawaguchi","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2026080404552371000_16.8.e119999.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2026080404552371000_16.8.e119999.33","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.5.333"},{"key":"2026080404552371000_16.8.e119999.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2508"},{"key":"2026080404552371000_16.8.e119999.35","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1200\/JCO.2001.19.11.2898","article-title":"Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study","volume":"19","author":"Mercadante","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026080404552371000_16.8.e119999.36","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3"},{"key":"2026080404552371000_16.8.e119999.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12904-022-01076-2","article-title":"Methadone switching for refractory cancer pain","volume":"21","author":"Ding","year":"2022","journal-title":"BMC Palliat Care"},{"key":"2026080404552371000_16.8.e119999.38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","article-title":"Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Swarm","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2026080404552371000_16.8.e119999.39","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","article-title":"Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?","volume":"16","author":"Ripamonti","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026080404552371000_16.8.e119999.40","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/jpm.2015.0525","article-title":"Methadone as a Coanalgesic for Palliative Care Cancer Patients","volume":"19","author":"Courtemanche","year":"2016","journal-title":"J Palliat Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-119999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:56:51Z","timestamp":1785844611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-119999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,4]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2026-119999"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-119999","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}